Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,461 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07669415RecruitingPhase 2
LM-168 combined with other treatments for advanced solid tumors
This trial tests a new drug called LM-168, either alone or combined with another cancer treatment, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07117461Recruiting
Distress screening program for newly diagnosed cancer patients
This study tests a program that screens for distress and connects you to support services shortly after a cancer diagnosis. It aims to improve emotional well-being and quality of care.
New York, New YorkAges 18 years+ - NCT06081907RecruitingPhase 1/Phase 2
IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors, focusing on lung cancer and melanoma. It aims to see if the drug is safe and effective, especially for those whose previous treatments have stopped working.
Changsha, HunanAges 18–75 - NCT07268040RecruitingPhase 2
Study of SHR-7787 injection plus other cancer drugs for solid tumors
This trial is testing a new drug, SHR-7787, combined with other cancer treatments for people with advanced solid tumors that cannot be removed by surgery. The goal is to see if this combination can help shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT06710158RecruitingPhase 1
SC-102 for advanced solid tumors
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07381829RecruitingPhase 1
HC010 plus chemotherapy for advanced lung cancer
This trial tests an experimental drug called HC010 combined with chemotherapy for people with advanced lung cancer, including certain types of non-small cell or small cell lung cancer. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07529002Recruiting
New PET scan imaging test for solid tumors
This trial tests a new type of PET scan (a special imaging test) called 89Zr-s-C1 to help detect and monitor solid tumors like melanoma, gastric cancer, or colorectal cancer. The scan may help doctors see tumors more clearly and track whether treatment is working.
Beijing, Beijing MunicipalityAges 15–70 - NCT07229638RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for solid tumors
This study tests a new drug called SHR-9839 given under the skin, combined with other anti-cancer treatments, for people with solid tumors. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT06651593RecruitingPhase 2
BND-22 and cemiplimab for advanced solid tumors
This trial tests a combination of two new drugs, BND-22 and cemiplimab, for people with certain advanced solid tumors like lung, colorectal, or ovarian cancer. It aims to see if this treatment helps control the cancer and looks at specific markers in your blood and tissue.
Houston, TexasAges 18 years+ - NCT06716619RecruitingPhase 1
Immune cell therapy for advanced solid tumors
This trial tests a new immune cell treatment made from your own lymph nodes for advanced solid tumors that haven't responded to standard therapies or have no good treatment options. It aims to see if this personalized cell therapy is safe and can help shrink tumors.
Guangzhou, GaungdongAges 18–75 - NCT07541573RecruitingPhase 1
GTB-5550 study for advanced solid tumors
This is an early-stage study testing a new drug called GTB-5550 in people with advanced cancers that have spread. The study aims to find the right dose and see if the drug helps shrink tumors.
Minneapolis, MinnesotaAges 18 years+ - NCT06169579Enrolling by invitationPhase 1
Trial of ND-003 for advanced solid cancers
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Xiamen, FujianAges 18 years+ - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06710379RecruitingPhase 1
Testing ADRX-0405 for advanced solid tumors
This trial tests a new drug called ADRX-0405 in people with advanced solid tumors like prostate, stomach, or lung cancer. The goal is to see how safe it is and if it shrinks tumors.
Duarte, CaliforniaAges 18 years+ - NCT07130383RecruitingPhase 2
Study of two experimental drugs for advanced breast cancer and other solid tumors
This trial tests a combination of two investigational drugs, MHB036C and MHB039A, in people with advanced breast cancer or other solid tumors that have spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07477743RecruitingPhase 1
Study of a new drug combo for advanced solid tumors
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
BeijingAges 18–75 - NCT05101070RecruitingPhase 1/Phase 2
Study of an anti-cancer drug alone or with immunotherapy
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Los Angeles, CaliforniaAges 18 years+ - NCT07055594RecruitingPhase 1/Phase 2
Study of SOA101 for advanced solid tumors
This trial tests a new drug called SOA101 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink tumors.
TaichungAges 18 years+ - NCT07158918RecruitingPhase 1/Phase 2
Trial of ABL103 with pembrolizumab and chemo for advanced solid tumors
This trial tests a new drug called ABL103 combined with pembrolizumab (immunotherapy) and with or without a chemotherapy drug called taxane. It is for people with advanced or metastatic solid tumors that have stopped responding to standard treatments or cannot tolerate them.
Cleveland, OhioAges 18 years+ - NCT06014502RecruitingPhase 1
Study of IMGS-001 for advanced solid tumors that returned after treatment
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Gilbert, ArizonaAges 18 years+ - NCT07382531RecruitingPhase 1/Phase 2
OH2 and BS006 injection for advanced solid tumors
This trial tests a combination of two injections, OH2 and BS006, for people with advanced solid tumors that have not responded to standard treatments. The injections are given directly into the tumor, aiming to shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT06644300RecruitingPhase 1
Study of BM230 for advanced solid tumors with HER2
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
Brisbane, QueenslandAges 18 years+ - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT07290088RecruitingPhase 2/Phase 3
Testing a new drug for advanced solid tumors
This trial tests a new drug called PRL3-zumab for people with advanced solid tumors (cancers that have spread). The goal is to see if it can shrink tumors or slow their growth. It is an option for patients who have had limited prior treatments.
Kota BharuAges 18–75
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,461 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.